GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma

Jorge A. Marrero, Patrick R. Romano, Olga Nikolaeva, Laura Steel, Anand Mehta, Claus J. Fimmel, Mary Ann Comunale, Anthony D'Amelio, Anna S. Lok, Timothy M. Block

Research output: Contribution to journalArticle

246 Citations (Scopus)

Abstract

Background/Aims: Golgi protein-73 (GP73) is up-regulated in hepatocellular carcinoma (HCC). The aims of this study were to determine if GP73 is detected in the serum, and to establish the sensitivity and specificity of serum GP73 for diagnosing HCC. Methods: Serum GP73 was detected by immunoblots and quantified by densitometric analysis. Results: A total of 352 patients were studied. Serum GP73 levels were significantly higher in patients with HCC compared to those with cirrhosis (P<0.001). GP73 had a sensitivity of 69% and a specificity of 75% at the optimal cutoff point of 10 relative units, with an area under the receiver operating curve of 0.79 vs. 0.61 for AFP (P=0.001). GP73 levels had significantly higher sensitivity (62%) than AFP (25%) for diagnosing early HCC (P<0.0001). Moreover, GP73 levels were elevated in the serum of 57% (32/56) of individuals with HCC who had serum AFP levels less than 20 ng/ml. Conclusions: Higher levels of GP73 can be found in the serum of patients with HCC than of those without. GP73 was better than AFP for the diagnosis of early HCC. Further validation studies are needed to confirm the role of GP73 in the early detection of HCC.

Original languageEnglish (US)
Pages (from-to)1007-1012
Number of pages6
JournalJournal of Hepatology
Volume43
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Hepatocellular Carcinoma
Glycoproteins
Biomarkers
Proteins
Blood Proteins
Serum
Validation Studies
Fibrosis
Sensitivity and Specificity

Keywords

  • Alpha fetoprotein
  • Cirrhosis
  • Early detection
  • Golgi protein 73
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Marrero, J. A., Romano, P. R., Nikolaeva, O., Steel, L., Mehta, A., Fimmel, C. J., ... Block, T. M. (2005). GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. Journal of Hepatology, 43(6), 1007-1012. https://doi.org/10.1016/j.jhep.2005.05.028

GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. / Marrero, Jorge A.; Romano, Patrick R.; Nikolaeva, Olga; Steel, Laura; Mehta, Anand; Fimmel, Claus J.; Comunale, Mary Ann; D'Amelio, Anthony; Lok, Anna S.; Block, Timothy M.

In: Journal of Hepatology, Vol. 43, No. 6, 12.2005, p. 1007-1012.

Research output: Contribution to journalArticle

Marrero, JA, Romano, PR, Nikolaeva, O, Steel, L, Mehta, A, Fimmel, CJ, Comunale, MA, D'Amelio, A, Lok, AS & Block, TM 2005, 'GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma', Journal of Hepatology, vol. 43, no. 6, pp. 1007-1012. https://doi.org/10.1016/j.jhep.2005.05.028
Marrero, Jorge A. ; Romano, Patrick R. ; Nikolaeva, Olga ; Steel, Laura ; Mehta, Anand ; Fimmel, Claus J. ; Comunale, Mary Ann ; D'Amelio, Anthony ; Lok, Anna S. ; Block, Timothy M. / GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. In: Journal of Hepatology. 2005 ; Vol. 43, No. 6. pp. 1007-1012.
@article{73c94d3df2804efab93e00e28c7b8a13,
title = "GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma",
abstract = "Background/Aims: Golgi protein-73 (GP73) is up-regulated in hepatocellular carcinoma (HCC). The aims of this study were to determine if GP73 is detected in the serum, and to establish the sensitivity and specificity of serum GP73 for diagnosing HCC. Methods: Serum GP73 was detected by immunoblots and quantified by densitometric analysis. Results: A total of 352 patients were studied. Serum GP73 levels were significantly higher in patients with HCC compared to those with cirrhosis (P<0.001). GP73 had a sensitivity of 69{\%} and a specificity of 75{\%} at the optimal cutoff point of 10 relative units, with an area under the receiver operating curve of 0.79 vs. 0.61 for AFP (P=0.001). GP73 levels had significantly higher sensitivity (62{\%}) than AFP (25{\%}) for diagnosing early HCC (P<0.0001). Moreover, GP73 levels were elevated in the serum of 57{\%} (32/56) of individuals with HCC who had serum AFP levels less than 20 ng/ml. Conclusions: Higher levels of GP73 can be found in the serum of patients with HCC than of those without. GP73 was better than AFP for the diagnosis of early HCC. Further validation studies are needed to confirm the role of GP73 in the early detection of HCC.",
keywords = "Alpha fetoprotein, Cirrhosis, Early detection, Golgi protein 73, Hepatocellular carcinoma",
author = "Marrero, {Jorge A.} and Romano, {Patrick R.} and Olga Nikolaeva and Laura Steel and Anand Mehta and Fimmel, {Claus J.} and Comunale, {Mary Ann} and Anthony D'Amelio and Lok, {Anna S.} and Block, {Timothy M.}",
year = "2005",
month = "12",
doi = "10.1016/j.jhep.2005.05.028",
language = "English (US)",
volume = "43",
pages = "1007--1012",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma

AU - Marrero, Jorge A.

AU - Romano, Patrick R.

AU - Nikolaeva, Olga

AU - Steel, Laura

AU - Mehta, Anand

AU - Fimmel, Claus J.

AU - Comunale, Mary Ann

AU - D'Amelio, Anthony

AU - Lok, Anna S.

AU - Block, Timothy M.

PY - 2005/12

Y1 - 2005/12

N2 - Background/Aims: Golgi protein-73 (GP73) is up-regulated in hepatocellular carcinoma (HCC). The aims of this study were to determine if GP73 is detected in the serum, and to establish the sensitivity and specificity of serum GP73 for diagnosing HCC. Methods: Serum GP73 was detected by immunoblots and quantified by densitometric analysis. Results: A total of 352 patients were studied. Serum GP73 levels were significantly higher in patients with HCC compared to those with cirrhosis (P<0.001). GP73 had a sensitivity of 69% and a specificity of 75% at the optimal cutoff point of 10 relative units, with an area under the receiver operating curve of 0.79 vs. 0.61 for AFP (P=0.001). GP73 levels had significantly higher sensitivity (62%) than AFP (25%) for diagnosing early HCC (P<0.0001). Moreover, GP73 levels were elevated in the serum of 57% (32/56) of individuals with HCC who had serum AFP levels less than 20 ng/ml. Conclusions: Higher levels of GP73 can be found in the serum of patients with HCC than of those without. GP73 was better than AFP for the diagnosis of early HCC. Further validation studies are needed to confirm the role of GP73 in the early detection of HCC.

AB - Background/Aims: Golgi protein-73 (GP73) is up-regulated in hepatocellular carcinoma (HCC). The aims of this study were to determine if GP73 is detected in the serum, and to establish the sensitivity and specificity of serum GP73 for diagnosing HCC. Methods: Serum GP73 was detected by immunoblots and quantified by densitometric analysis. Results: A total of 352 patients were studied. Serum GP73 levels were significantly higher in patients with HCC compared to those with cirrhosis (P<0.001). GP73 had a sensitivity of 69% and a specificity of 75% at the optimal cutoff point of 10 relative units, with an area under the receiver operating curve of 0.79 vs. 0.61 for AFP (P=0.001). GP73 levels had significantly higher sensitivity (62%) than AFP (25%) for diagnosing early HCC (P<0.0001). Moreover, GP73 levels were elevated in the serum of 57% (32/56) of individuals with HCC who had serum AFP levels less than 20 ng/ml. Conclusions: Higher levels of GP73 can be found in the serum of patients with HCC than of those without. GP73 was better than AFP for the diagnosis of early HCC. Further validation studies are needed to confirm the role of GP73 in the early detection of HCC.

KW - Alpha fetoprotein

KW - Cirrhosis

KW - Early detection

KW - Golgi protein 73

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=27744539432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744539432&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2005.05.028

DO - 10.1016/j.jhep.2005.05.028

M3 - Article

C2 - 16137783

AN - SCOPUS:27744539432

VL - 43

SP - 1007

EP - 1012

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 6

ER -